PHARMACOECONOMIC STUDY OF THE USE OF DRUG SOLIFENACIN FOR THE TREATMENT OF URGE URINARY INCONTINENCE IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME
- Authors: Avksentyeva M.V1,2, Gerasimova K.V1,2, Khachatryan G.R1, Frolov M.Y.3,4, Omelyanovsky V.V1, Avksentyev N.A1,5
-
Affiliations:
- Russian Presidential Academy of National Economy and Public Administration
- First MSMU n.a. I.M. Sechenov
- Volgograd State Medical University
- IPO «Interregional Association of Clinical Pharmacologists»
- Scientific Research Financial Institute
- Issue: No 5 (2014)
- Pages: 56-61
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/280292
- ID: 280292
Cite item
Abstract
Full Text
About the authors
M. V Avksentyeva
Russian Presidential Academy of National Economy and Public Administration; First MSMU n.a. I.M. SechenovCenter for the Evaluation of Technologies in Health Care; Department of Public Health and Preventive Medicine
K. V Gerasimova
Russian Presidential Academy of National Economy and Public Administration; First MSMU n.a. I.M. SechenovCenter for the Evaluation of Technologies in Health Care; Department of Public Health and Preventive Medicine
G. R Khachatryan
Russian Presidential Academy of National Economy and Public AdministrationCenter for the Evaluation of Technologies in Health Care
M. Yu. Frolov
Volgograd State Medical University; IPO «Interregional Association of Clinical Pharmacologists»
Email: mufrolov66@gmail.com
PhD in Medical Sciences, Associate Professor of the Course of FAT at the Department of Clinical Pharmacology and Critical Care; Head of the expert group
V. V Omelyanovsky
Russian Presidential Academy of National Economy and Public AdministrationCenter for the Evaluation of Technologies in Health Care
N. A Avksentyev
Russian Presidential Academy of National Economy and Public Administration; Scientific Research Financial InstituteCenter for the Evaluation of Regional Reforms
References
- Abrams P., Artibani W., Cardozo L. et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2006; 25: 293.
- Abrams P., Cardozo L., Fall M. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21: 167-178.
- Chapple C., Artibani W., Cardozo L. et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005; 95: 335-340.
- Brown J., McGhan W., Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000; 6(11): 574-579.
- Brown J., Vittinghoff E, Wyman J. et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000; 48(7): 721-725.
- Castro Diaz D., Rebollo P., Gonzalez-Segura Alsina D. Comorbidity associated to overactive bladder syndrome. Arch Esp Urol. 2009; 62(8): 639-645.
- Hasegawa J., Kuzuya M., Iguchi A. Urinary incontinence and behavioural symptoms are independent risk factors for recurrent and injurious falls, respectively, among residents in long-term care facilities. Arch Gerontol Geriatr. 2010; 50(1): 77-81.
- Johansson C., Molander U., Milsom I. et al. Association between urinary incontinence and urinary tract infections, and fractures in postmenopausal women. Maturitas. 1996; 23(3): 265-271.
- Wagner T., Hu T., Bentkover J. et al. Health-related consequences of overactive bladder. Am J Manag Care. 2002; 8(19): 598-607.
- Irwin D., Milsom I., Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50: 1306-1315.
- Milsom I., Abrams P., Cardoza L. et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87: 760-766.
- Stewart W., Van Rooyen J., Cundiff G. et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20: 327-336.
- Пушкарь Д.Ю. Гиперактивный мочевой пузырь у женщин. М.: МЕДпресс-информ. 2003. 160 с.
- Bolge S.C., Cerulli A., Kahler K.H. et al. Impact of successful treatment of overactive bladder on health care resource use and productivity. DrugBenefit Trends. 2006; 18: 244-255.
- Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology. 1997; 50: 100-107.
- Chapple C., Arano P., Bosch J. et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004; 93(1): 71-77.
- Armstrong E.P., Malone D.C. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. Journal of Medical Economics. 2012; 15: 35-44.
- Cardozo L., Thorpe A., Warner J. et al. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patientswith overactive bladder in the UK National Health Service. BJU International. 2010; 106: 506-514.
- Hakkaart L., Verboom P., Phillips R. et al. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol. 2009; 41: 293-298.
- Speakman M., Khullar V., Mundy A. et al. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin. 2008; 24(8): 2173-2179.
- Zinner N., Noe L. et al. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Current medical research and opinion. 2008; 24: 1583-1591.
- Guzman A. et al. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model. BMC Urology. 2011; 11:9.
- Kobelt G., Johnson L., Mattiasson A. Cost effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodynam. 1998; 17: 599-611.
- Рациональная фармакотерапия в урологии. Руководство для практикующих врачей // Под общей ред. Лопаткина Н.А., Перепановой Т.С. М.: «Литтерра». 2006.
- Клинико-экономический анализ // Под ред. П.А. Воробьева. М.: Ньюдиамед. 2008.